NFCR research on blood cancer
The Future of Blood Cancer Research
Blood cancer research includes work on blood-forming stem cells, experimental compounds against leukemia cells and the genetic mechanisms that influence cancer growth and treatment resistance. These approaches address different questions and stages of development. Laboratory findings need further testing before they can become established treatments.
What NFCR Is Doing
We support research into blood-forming stem cells, experimental therapies and the genetic mechanisms of cancer. Curt Civin’s work on CD34 helped scientists isolate blood-forming stem cells for transplantation, and his later laboratory studies investigated compounds against AML cells. We began supporting Wei Zhang’s genomics research in 2006 and supported Michael Sporn’s chemoprevention research from 1999 to 2015. Our current and past-supported researchers address blood cancers and broader questions that may inform progress across cancer types.
- Year Curt Civin discovered CD34, a marker that helped enable isolation of blood-forming stem cells
- 1984
- Year we began supporting Wei Zhang’s cancer genomics research
- 2006
- Years of our support for Michael Sporn’s research
- 1999–2015